BCLI BRAINSTORM CELL THERAPEUTICS INC.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1137883 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY6.4%
TTM EPS YoY38.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-914.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1,568.1%
Debt / equity—
Current ratio0.03x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-584.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $4.17M | $4.65M | $10.75M | $13.96M | $15.23M |
| SG&A expense | $5.78M | $7.04M | $10.69M | $10.87M | $9.30M |
| Operating income | -$9.95M | -$11.69M | -$21.44M | -$24.82M | -$24.54M |
| Pretax income | -$10.31M | -$11.62M | -$17.19M | -$24.28M | -$24.46M |
| Net income | -$10.31M | -$11.62M | -$17.19M | -$24.28M | -$24.46M |
| EBITDA | -$9.75M | -$11.45M | -$21.17M | -$24.54M | -$24.28M |
| EPS (basic) | -1.11 | -2.31 | -6.00 | -0.66 | -0.68 |
| EPS (diluted) | -1.11 | -2.31 | -6.00 | -0.66 | -0.68 |
| Weighted avg. shares (diluted) | 9.27M | 5.02M | 2.87M | 36.51M | 36.18M |
| Balance sheet | |||||
| Cash & equivalents | $29,000 | $371,000 | $1.49M | $772,000 | $18.86M |
| Short-term investments | — | — | — | $2.21M | $3.24M |
| Current assets | $307,000 | $385,000 | $1.90M | $3.11M | $23.28M |
| PP&E, net | $235,000 | $434,000 | $686,000 | $933,000 | $1.19M |
| Total assets | $1.02M | $1.83M | $4.21M | $8.45M | $29.28M |
| Current liabilities | $11.01M | $8.98M | $7.80M | $8.80M | $6.32M |
| Short-term debt | $967,000 | $300,000 | — | — | — |
| Total liabilities | $11.01M | $9.60M | $9.07M | $11.47M | $9.94M |
| Shareholders' equity | -$9.98M | -$7.76M | -$4.86M | -$3.02M | $19.34M |
| Shares outstanding | 11.03M | 6.14M | 4.03M | 36.69M | 36.40M |
| Cash flow statement | |||||
| Operating cash flow | -$6.97M | -$9.09M | -$20.46M | -$19.32M | -$26.27M |
| Capital expenditure | — | — | $18,000 | $29,000 | $330,000 |
| Free cash flow | — | — | -$20.48M | -$19.35M | -$26.59M |
| Investing cash flow | — | $12,000 | $2.19M | $998,000 | $323,000 |
| Financing cash flow | $6.88M | $7.97M | $18.98M | $238,000 | $6.97M |
| Depreciation & amortization | $199,000 | $240,000 | $265,000 | $285,000 | $260,000 |
| Stock-based compensation | $1.52M | $698,000 | $1.49M | $1.68M | $1.37M |
Free plan shows the latest 5 periods; Pro shows all 24 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.